Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SELECTIVE DOPAMINE D-4 RECEPTOR ANTAGONISTS
Autore:
SANNER MA;
Indirizzi:
PFIZER INC,CENT RES,EASTERN POINT RD GROTON CT 06340
Titolo Testata:
Expert opinion on therapeutic patents
fascicolo: 4, volume: 8, anno: 1998,
pagine: 383 - 393
SICI:
1354-3776(1998)8:4<383:SDDRA>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
D4 RECEPTORS; NOVELTY SEEKING; HIGH-AFFINITY; BINDING; GENE; SCHIZOPHRENIA; POLYMORPHISM; ASSOCIATION; EXPRESSION; CLOZAPINE;
Keywords:
ANTIPSYCHOTIC; CP-226,269; CP-293,019; DOPAMINE D-4 ANTAGONIST; L-745,870; NGD 94-1; NRA0045; PD-172,938; PD-82,011; PNU-101,387; SCHIZOPHRENIA; U-99363E; YM-43611; YM-50001;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
138
Recensione:
Indirizzi per estratti:
Citazione:
M.A. Sanner, "SELECTIVE DOPAMINE D-4 RECEPTOR ANTAGONISTS", Expert opinion on therapeutic patents, 8(4), 1998, pp. 383-393

Abstract

The discovery that the atypical antipsychotic clozapine has higher affinity for the dopamine D-4 receptor relative to the D-2 receptor touched off a search for more potent, highly selective D-4 antagonists as a new class of antipsychotics. Many compounds achieving high potency and selectivity are now available including L-745,870 (Merck), NGD 94-1(Neurogen), PNU-101,387 (Pharmacia & Upjohn), CP-293,019 (Pfizer), and PD-172,938 (Warner-Lambert). Unfortunately, L-745,870 did not improve psychotic symptoms in a Phase II clinical trial, causing many researchers to question the role of the D-4 receptor in the aetiology of schizophrenia. Recent findings with new biological models and D-4 selective agonists may help clarify D-4 receptor physiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 01:07:42